• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

焦虑水平可预测口服双膦酸盐治疗的绝经后妇女的骨密度:一项为期两年的随访研究。

Anxiety Levels Predict Bone Mineral Density in Postmenopausal Women Undergoing Oral Bisphosphonates: A Two-Year Follow-Up.

机构信息

Department of Clinical and Experimental Medicine, University Hospital of Messina, 98122 Messina, Italy.

Department of Cognitive Sciences, Psychology, Education and Cultural Studies, University of Messina, 98121 Messina, Italy.

出版信息

Int J Environ Res Public Health. 2021 Jul 31;18(15):8144. doi: 10.3390/ijerph18158144.

DOI:10.3390/ijerph18158144
PMID:34360437
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8346074/
Abstract

Clinical psychological factors may predict medical diseases. Anxiety level has been associated with osteoporosis, but its role on bone mineral density (BMD) change is still unknown. This study aimed to investigate the association between anxiety levels and both adherence and treatment response to oral bisphosphonates (BPs) in postmenopausal osteoporosis. BMD and anxiety levels were evaluated trough dual-energy X-ray absorptiometry and the Hamilton Anxiety Rating Scale (HAM-A), respectively. Participants received weekly medication with alendronate or risedronate and were grouped according to the HAM-A scores into tertiles (HAM-A 3 > HAM-A 2 > HAM-A 1). After 24 months, BMD changes were different among the HAM-A tertiles. The median lumbar BMD change was significantly greater in both the HAM-A 2 and HAM-A 3 in comparison with the HAM-A 1. The same trend was observed for femoral BMD change. Adherence to BPs was >75% in 68% of patients in the HAM-A 1, 79% of patients in the HAM-A 2, and 89% of patients in the HAM-A 3 ( = 0.0014). After correcting for age, body mass index, depressive symptoms, and the 10-yr. probability of osteoporotic fractures, anxiety levels independently predicted lumbar BMD change (β = 0.3417, SE 0.145, = 0.02). In conclusion, women with higher anxiety levels reported greater BMD improvement, highlighting that anxiety was associated with adherence and response to osteoporosis medical treatment, although further research on this topic is needed.

摘要

临床心理因素可能预测医学疾病。焦虑水平与骨质疏松症有关,但它对骨密度(BMD)变化的作用尚不清楚。本研究旨在探讨焦虑水平与绝经后骨质疏松症患者口服双膦酸盐(BPs)的依从性和治疗反应之间的关系。BMD 和焦虑水平分别通过双能 X 射线吸收法和汉密尔顿焦虑量表(HAM-A)进行评估。参与者每周接受阿伦膦酸盐或利塞膦酸盐治疗,并根据 HAM-A 评分分为三分位(HAM-A3>HAM-A2>HAM-A1)。24 个月后,HAM-A 三分位之间的 BMD 变化不同。与 HAM-A1 相比,HAM-A2 和 HAM-A3 的腰椎 BMD 变化中位数显著更大。股骨 BMD 变化也呈现出相同的趋势。在 HAM-A1 中,有 68%的患者 BPs 依从性>75%,在 HAM-A2 中,有 79%的患者 BPs 依从性>75%,在 HAM-A3 中,有 89%的患者 BPs 依从性>75%(=0.0014)。在校正年龄、体重指数、抑郁症状和 10 年骨质疏松性骨折概率后,焦虑水平独立预测腰椎 BMD 变化(β=0.3417,SE 0.145,=0.02)。总之,焦虑水平较高的女性报告 BMD 改善更大,这表明焦虑与骨质疏松症治疗的依从性和反应有关,但需要进一步研究这一课题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7e/8346074/ea5a4a4731a6/ijerph-18-08144-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7e/8346074/547769138e4f/ijerph-18-08144-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7e/8346074/ea5a4a4731a6/ijerph-18-08144-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7e/8346074/547769138e4f/ijerph-18-08144-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7e/8346074/ea5a4a4731a6/ijerph-18-08144-g002.jpg

相似文献

1
Anxiety Levels Predict Bone Mineral Density in Postmenopausal Women Undergoing Oral Bisphosphonates: A Two-Year Follow-Up.焦虑水平可预测口服双膦酸盐治疗的绝经后妇女的骨密度:一项为期两年的随访研究。
Int J Environ Res Public Health. 2021 Jul 31;18(15):8144. doi: 10.3390/ijerph18158144.
2
Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.绝经后骨质疏松症停止口服双膦酸盐治疗对骨转换标志物和骨密度的影响。
Osteoporos Int. 2018 Jun;29(6):1407-1417. doi: 10.1007/s00198-018-4460-6. Epub 2018 Mar 10.
3
Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.三种口服双膦酸盐疗法对绝经后骨质疏松症患者外周骨骼影响的比较:TRIO研究
Osteoporos Int. 2014 Dec;25(12):2729-41. doi: 10.1007/s00198-014-2817-z. Epub 2014 Jul 30.
4
Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.绝经后原发性骨质疏松症女性双膦酸盐治疗失败的相关因素。
Osteoporos Int. 2014 Apr;25(4):1401-10. doi: 10.1007/s00198-014-2619-3. Epub 2014 Feb 8.
5
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.在绝经后女性中,尽管先前使用口服双膦酸盐治疗效果欠佳但仍处于较高骨折风险的情况下,与每月口服伊班膦酸钠和利塞膦酸钠相比,地诺单抗可显著提高骨密度并降低骨转换。
Osteoporos Int. 2014 Jul;25(7):1953-61. doi: 10.1007/s00198-014-2692-7. Epub 2014 Mar 28.
6
Interrelations between clinical-psychological features and bone mineral density changes in post-menopausal women undergoing anti-osteoporotic treatment: a two-year follow-up.绝经后妇女抗骨质疏松治疗中临床心理学特征与骨密度变化的相互关系:为期两年的随访。
Front Endocrinol (Lausanne). 2023 May 9;14:1151199. doi: 10.3389/fendo.2023.1151199. eCollection 2023.
7
Anxiety levels predict fracture risk in postmenopausal women assessed for osteoporosis.焦虑水平可预测接受骨质疏松症评估的绝经后妇女的骨折风险。
Menopause. 2018 Oct;25(10):1110-1115. doi: 10.1097/GME.0000000000001123.
8
Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.低剂量阿仑膦酸钠治疗对中国绝经后骨质疏松和骨量减少症妇女骨密度和骨转换标志物的影响。
Menopause. 2013 Jan;20(1):72-8. doi: 10.1097/gme.0b013e31825fe2e8.
9
Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.绝经后骨质疏松症患者中每周一次的通用和原研品牌双膦酸盐在持久性、安全性和疗效方面的差异:回顾性患者病历分析的 1 年结果。
Rheumatol Int. 2009 Dec;30(2):213-21. doi: 10.1007/s00296-009-0940-5.
10
Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.老年日本骨质疏松症女性腰椎骨密度对阿仑膦酸盐治疗一年反应的决定因素。
Yonsei Med J. 2004 Aug 31;45(4):676-82. doi: 10.3349/ymj.2004.45.4.676.

引用本文的文献

1
Pain in Osteoporosis: Current and Future Strategies.骨质疏松症中的疼痛:当前与未来策略
Drugs Aging. 2025 Jul 9. doi: 10.1007/s40266-025-01225-1.
2
Defense mechanisms in immune-mediated diseases: a cross-sectional study focusing on Severe Allergic Asthma and Hymenoptera Venom Anaphylaxis patients.免疫介导疾病中的防御机制:一项针对严重过敏性哮喘和膜翅目毒液过敏反应患者的横断面研究。
Front Psychol. 2025 Jun 18;16:1608335. doi: 10.3389/fpsyg.2025.1608335. eCollection 2025.
3
Interrelations between clinical-psychological features and bone mineral density changes in post-menopausal women undergoing anti-osteoporotic treatment: a two-year follow-up.

本文引用的文献

1
Retrospective Analyses of Psychological Distress and Defense Style Among Cancer Patients.癌症患者心理困扰与防御方式的回顾性分析
Clin Neuropsychiatry. 2020 Aug;17(4):217-224. doi: 10.36131/cnfioritieditore20200403.
2
Psychological Distress Among Healthcare Professionals Involved in the Covid-19 Emergency: Vulnerability and Resilience Factors.参与新冠疫情应急工作的医护人员的心理困扰:脆弱性和复原力因素
Clin Neuropsychiatry. 2020 Apr;17(2):94-96. doi: 10.36131/CN20200212.
3
Vitamin D Boosts Alendronate Tail Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis.
绝经后妇女抗骨质疏松治疗中临床心理学特征与骨密度变化的相互关系:为期两年的随访。
Front Endocrinol (Lausanne). 2023 May 9;14:1151199. doi: 10.3389/fendo.2023.1151199. eCollection 2023.
4
Mindfulness and Defense Mechanisms as Explicit and Implicit Emotion Regulation Strategies against Psychological Distress during Massive Catastrophic Events.正念和防御机制作为明确和内隐的情绪调节策略,以应对大规模灾难性事件期间的心理困扰。
Int J Environ Res Public Health. 2022 Oct 4;19(19):12690. doi: 10.3390/ijerph191912690.
5
Editorial: Psychological Factors as Determinants of Medical Conditions, Volume II.社论:作为医疗状况决定因素的心理因素,第二卷
Front Psychol. 2022 Mar 21;13:865235. doi: 10.3389/fpsyg.2022.865235. eCollection 2022.
6
Common osteoporosis drug associated with increased rates of depression and anxiety.常用骨质疏松药物与抑郁和焦虑发生率增加相关。
Sci Rep. 2021 Dec 14;11(1):23956. doi: 10.1038/s41598-021-03214-x.
维生素 D 可增强阿仑膦酸钠对绝经后骨质疏松症妇女骨密度的持续作用。
Nutrients. 2021 May 31;13(6):1878. doi: 10.3390/nu13061878.
4
Roles of Anxiety and Depression in Predicting Cardiovascular Disease Among Patients With Type 2 Diabetes Mellitus: A Machine Learning Approach.焦虑和抑郁在预测2型糖尿病患者心血管疾病中的作用:一种机器学习方法。
Front Psychol. 2021 Apr 28;12:645418. doi: 10.3389/fpsyg.2021.645418. eCollection 2021.
5
Vitamin D, Bone Metabolism, and Fracture Risk in Polycystic Ovary Syndrome.多囊卵巢综合征中的维生素D、骨代谢与骨折风险
Metabolites. 2021 Feb 18;11(2):116. doi: 10.3390/metabo11020116.
6
Psychological Factors as Determinants of Chronic Conditions: Clinical and Psychodynamic Advances.作为慢性病决定因素的心理因素:临床与精神动力学进展
Front Psychol. 2021 Jan 28;12:635708. doi: 10.3389/fpsyg.2021.635708. eCollection 2021.
7
Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study.住院患者使用胆钙化醇对合并 COVID-19 患者临床结局的影响:一项产生假说的研究。
Nutrients. 2021 Jan 14;13(1):219. doi: 10.3390/nu13010219.
8
Usefulness of advanced-platelet rich fibrin (A-PRF) and injectable-platelet rich fibrin (i-PRF) in the management of a massive medication-related osteonecrosis of the jaw (MRONJ): A 5-years follow-up case report.富含血小板纤维蛋白(A-PRF)和可注射性富含血小板纤维蛋白(i-PRF)在治疗大剂量药物相关性颌骨坏死(MRONJ)中的应用:5 年随访病例报告。
Indian J Dent Res. 2020 Sep-Oct;31(5):813-818. doi: 10.4103/ijdr.IJDR_689_19.
9
The Relationship Between Vitamin D and Telomere/Telomerase: A Comprehensive Review.维生素 D 与端粒/端粒酶的关系:全面综述。
J Frailty Aging. 2021;10(1):2-9. doi: 10.14283/jfa.2020.33.
10
The Case of Medication-Related Osteonecrosis of the Jaw Addressed from a Pathogenic Point of View. Innovative Therapeutic Strategies: Focus on the Most Recent Discoveries on Oral Mesenchymal Stem Cell-Derived Exosomes.从发病机制角度探讨药物相关性颌骨坏死病例。创新治疗策略:聚焦口腔间充质干细胞衍生外泌体的最新发现。
Pharmaceuticals (Basel). 2020 Nov 25;13(12):423. doi: 10.3390/ph13120423.